Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 22;18(8):58.
doi: 10.1007/s11892-018-1024-2.

Monogenic Diabetes in Children and Adolescents: Recognition and Treatment Options

May Sanyoura  1 , Louis H Philipson  1 , Rochelle Naylor  2
Affiliations
Review

Monogenic Diabetes in Children and Adolescents: Recognition and Treatment Options

May Sanyoura et al. Curr Diab Rep. .

Abstract

Purpose of review: We provide a review of monogenic diabetes in young children and adolescents with a focus on recognition, management, and pharmacological treatment.

Recent findings: Monogenic forms of diabetes account for approximately 1-2% of diabetes in children and adolescents, and its incidence has increased in recent years due to greater awareness and wider availability of genetic testing. Monogenic diabetes is due to single gene defects that primarily affect beta cell function with more than 30 different genes reported. Children with antibody-negative, C-peptide-positive diabetes should be evaluated and genetically tested for monogenic diabetes. Accurate genetic diagnosis impacts treatment in the most common types of monogenic diabetes, including the use of sulfonylureas in place of insulin or other glucose-lowering agents or discontinuing pharmacologic treatment altogether. Diagnosis of monogenic diabetes can significantly improve patient care by enabling prediction of the disease course and guiding appropriate management and treatment.

Keywords: Genetic testing; Maturity-onset diabetes of the young; Monogenic diabetes; Syndromic diabetes; Type 1 diabetes; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest May Sanyoura, Louis H. Philipson, and Rochelle Naylor declare that they have no conflict of interest.

References

    1. Flannick J, Johansson S, Njølstad PR Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes. Nat Publ Group. 2016;12(7):1–13. 10.1038/nrendo.2016.50. - DOI - PubMed
    1. Vaxillaire M, Froguel P. Monogenic forms of diabetes mellitus: an update. Endocrinol Nutr. 2009;56 S4:26–9. 10.1016/S1575-0922(09)73513-2. - DOI - PubMed
    1. Alkorta-Aranburu G, Carmody D, Cheng YW, Nelakuditi V, Ma L, Dickens JT, et al. Phenotypic heterogeneity in monogenic diabetes: the clinical and diagnostic utility of a gene panel-based next-generation sequencing approach. Mol Genet Metab. 2014;113(4):315–20. 10.1016/j.ymgme.2014.09.007. - DOI - PMC - PubMed
    1. Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. Diabetologia. 2017;60(5):1–9. 10.1007/s00125-017-4226-2. Provides a review of the success of a precision medicine approach using monogenic forms of diabetes as an example. - DOI - PMC - PubMed
    1. Kleinberger JW, Pollin TI. Personalized medicine in diabetes mellitus: current opportunities and future prospects. Ann N Y Acad Sci. 2015;1346(1):45–56. 10.1111/nyas.12757. - DOI - PMC - PubMed